Final-Program-ATS-2023-AP.vp

48

SUNDAY • MAY 21

CLINICAL • TRANSLATIONAL MINI SYMPOSIUM

BASIC • TRANSLATIONAL POSTER DISCUSSION SESSION

A19

A21

LUNG CANCER SCREENING: WHERE THE RUBBER MEETS THE ROAD

INFECTION, LUNG INJURY, AND SEPSIS FROM MODELS TO TRANSLATION

9:00 a.m. - 11:00 a.m.

Walter E. Washington Convention Center Room 202 A (Level 2)

9:00 a.m. - 11:00 a.m.

Marriott Marquis Washington Marquis Ballroom, Salons 1-2 (Level M2)

Poster Viewing

9:00-9:45 9:45-11:00

Chairing: C.R. Sears, MD, ATSF, Indianapolis, IN M.C. Aldrich, MPH, PhD, Nashville, TN Oral Presentations: 9:00 Evaluation of Sex Differences in Lung Cancer Screening Outcomes Among Never-smokers/ Y.W. Kim, Seongnam, Korea, Republic of 9:12 Evaluating the Intersectionality of Race and Gender in Lung Screening Eligibility in the 2021 United States Preventive Services Task Force Lung Screening Guidelines/ A. Manful, Nashville, TN 9:24 What Makes Someone “Too Sick to Screen”? Factors Associated With Clinicians Deeming Patients Inappropriate for Lung Cancer Screening in the Veterans Health Administration/ E.R. Nunez, Springfield, MA 9:36 Recruiting and Retaining Patients for an Urban Comprehensive Lung Cancer Screening Program for Lung Nodules Coupled With Detection of Comorbid Conditions: Temple Healthy Chest Initiative (THCI)/ S.E. Murphy, Philadelphia, PA 9:48 Mammography and Tomography: A Tale of Two Screening Programs/ J.M.C. Sweetnam, Charleston, SC 10:00 Impact of Economic Hardship, Race, and Educational Attainment on Utilization of Electronic Communication Among Individuals Receiving Lung Cancer Screening/ C.S. Shusted, Philadelphia, PA 10:12 Quantifying the Economic Value of Reduced Health Disparities From Increased Rates of Low-Dose CT Screening for Lung Cancer/ J. Shafrin, Los Angeles, CA 10:24 Poor Lung Cancer Screening Outcomes Was Associated With Diabetes in a National Lung Screening Trial Subgroup (N=18,463)/ R.J. Scott, Auckland, New Zealand 10:36 Frequency of Radiology Non-concordance in Multi-disciplinary Review of Low-dose CTS for Lung Cancer Screening/ J.A. Barta, Philadelphia, PA 10:48 “What Is a Lung Nodule?” - Providers’ Answers and Analog Patients’ Preferences in the Communication of Lung Cancer Screening Results/ M. Ito Fukunaga, Worcester, MA

Discussion

Chairing: J.A. Masso Silva, PhD, La Jolla, CA A.N. Rizzo, MD, PhD, Boston, MA J.A. Hippensteel, MS, MD, Aurora, CO M. Hepokoski, MD, La Jolla, CA 101 Sleep Disruption Alters Cellular Immune Response to Endotoxin-mediated Sepsis/ M.T.Y. Lam, La Jolla, CA 102 Gasdermin-D-Dependent NETs Generation Promotes Cigarette-Smoke Induced Flu Severity/ T.W. Kaminski, Pittsburgh, PA 103 Cooperation of Immune Regulators Tollip and Surfactant Protein A Inhibits Influenza A Virus Infection in Mice/ N. Schaunaman, Denver, CO 104 The Protective Role of the Heme-scavanging Protein, Hemopexin, in Host Defense Against Invasive Pulmonary Aspergillosis/ G. Qu, Gainesville, FL 105 Mechanisms of Enhanced Streptococcus Pneumoniae Clearance Observed in Mertk-null Mice/ M.K. Mcpeek, Chapel Hill, NC 106 The Role of Peripherally-induced Regulatory T Cells in the Recovery From Influenza-induced Lung Injury/ M. Mccullough, Chapel Hill, NC 107 A Novel Next-generation Non-catalytic P38alpha/MK2 Immunomodulator With Endothelial-Barrier-Stabilizing and Anti-inflammatory Activity Mitigates LPS-induced Acute Lung Injury (ALI)/ J.D. Hasday, Baltimore, MD 108 LGM1506 Protects Against Ozone-Induced Lung Injury in Rhesus Macaques/ P.A. Hernandez, Davis, CA 109 Novel Oxidized Phospholipid Signatures and Epithelial Cell Cytotoxicity in THC-related Vaping-associated Lung Injury/ K. Lockwood, Pittsburgh, PA 110 IRL201104, a Novel Immunomodulatory Peptide, Prevents Inflammatory Infiltration and Proinflammatory Cytokine Release in a New Model of ARDS Associated to Influenza Infection/ J. De Alba, London, United Kingdom 111 Phagocytic Role of DHX58 During the Resolution of Pneumonia-ARDS in Mice/ A.F. Villabona-Rueda, Baltimore, MD

ATS 2023 • Washington, DC